GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XTX-301 overview
XTX-301 is under development for treatment of solid tumors including melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma, triple-negative breast cancer (TNBC), MSI-H/dMMR colorectal cancer, MSI-H/dMMR endometrial cancer, prostate cancer, ovarian cancer, pancreatic cancer, and microsatellite stable colorectal cancer. The drug candidate comprises of long-acting, tumour selective interleukin-12. The drug candidate is developed based on Aklusion and Switchblade platform technology.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
Xilio Therapeutics overview
Xilio Therapeutics is a biotechnology company that discovers and develops immuno-oncology therapeutics for the treatment of lung cancer. Xilio Therapeutics is headquartered in Waltham, Massachusetts, the US.
For a complete picture of XTX-301’s drug-specific PTSR and LoA scores, buy the report here.
